Blog artwork.jpg

Something Powerful

Tell The Reader More

The headline and subheader tells us what you're offering, and the form header closes the deal. Over here you can explain why your offer is so great it's worth filling out a form for.

Remember:

  • Bullets are great
  • For spelling out benefits and
  • Turning visitors into leads.

Medius Deal Watch October 2017

October 2017 has proved to be a very interesting month, with our Deal Watch top 20 table showing a significant absence of mergers and acquisitions and with far more licensing/co-development deals featuring. According to EvaluatePharma, only 31 M&A deals were announced in the period July – September, significantly below the quarterly average for the decade (56) and only fractionally above the 29 deals reported in Q2. Oncology remains the key theme this month, but broadening out to include approaches such as radiopharmaceuticals and vaccines. 

 

Licensor Acquired
Licensee Acquirer
Deal Type Headline ($m)

Amneal

Impax

Merger 9,000

Advanced Accelerator Applications

Novartis

Corporate acquisition 3,900

CureVac

Lilly

Licence and collaboration 1,803

CytomX

Amgen

Co-development, licence research 1,465

Alnylam Pharmaceuticals

Vir Biotechnology

Licence 1,000*
Click here to view the top 20 deals for October

 

The full report also contains:

  • Pharma forays into radiopharma
  • Infectious diseases are hot
  • Regional deals - alive and thriving
  • There’s safety in numbers
  • Not a vintage year so far

Want to read the complete report?

DOWNLOAD THE DEAL WATCH  OCTOBER 2017

 

Interested in reading the past issues? 

  • Download the Deal Watch September 2017 HERE
  • Download the Deal Watch August 2017 HERE
  • Download the Deal Watch July 2017 HERE
  • Download the Deal Watch May 2017 HERE
  • Download the Deal Watch April 2017 HERE
  • Download the Deal Watch March 2017 HERE
  • Download the Deal Watch February 2017 HERE
  • Download the Deal Watch January 2017 HERE
  • Download the 2016 annual review HERE
Sharon Finch
Written By

Add Your Response